NCT05218096 2025-01-09
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Terminated
Clinical Trials
14 trialsNCT02965573 2024-08-28
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
Phase 2 Completed
NCT03863080 2023-12-20
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Immunovant Sciences GmbH
Phase 2 Completed
NCT03772587 2023-06-27
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
Phase 2 Completed
NCT03896295 2023-06-27
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
Phase 2 Terminated
NCT04159805 2023-06-02
A Study of TAK-079 in People With Generalized Myasthenia Gravis
Takeda
Phase 2 Completed
NCT03315130 2022-07-27
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
UCB Pharma
Phase 2 Completed
NCT03052751 2021-08-03
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
UCB Pharma
Phase 2 Completed
NCT02100969 2021-06-02
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
University of Kansas Medical Center
Phase 2 Completed
NCT02473965 2020-03-30
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Grifols Therapeutics LLC
Phase 2 Completed
NCT02110706 2020-03-06
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
Yale University
Phase 2 Completed
NCT00727194 2019-09-24
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02473952 2019-03-05
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
Grifols Therapeutics LLC
Phase 2 Completed
NCT00814138 2016-05-26
Efficacy of Methotrexate in Myasthenia Gravis
University of Kansas Medical Center
Phase 2 Completed